Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a …
…, H Lawrence, R Valentine, ME Viljoen… - The Lancet …, 2022 - thelancet.com
Background The safety and immunogenicity profile of COVID-19 vaccines when administered
concomitantly with seasonal influenza vaccines have not yet been reported. We therefore …
concomitantly with seasonal influenza vaccines have not yet been reported. We therefore …
Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial
…, EC Thomson, J Turner, ME Viljoen… - Clinical Infectious …, 2023 - academic.oup.com
Background The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7%
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-…
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-…
Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B. 1.1. 7 variant
Background Covid-19 vaccines are urgently needed, especially against emerging variants.
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-…
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-…
[HTML][HTML] The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insight
…, EC Thomson, J Turner, ME Viljoen… - Epidemiology and …, 2024 - ncbi.nlm.nih.gov
To investigate the symptoms of SARS-CoV-2 infection, their dynamics and their discriminatory
power for the disease using longitudinally, prospectively collected information reported at …
power for the disease using longitudinally, prospectively collected information reported at …
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insight
…, PA Swift, EC Thomson, J Turner, ME Viljoen… - Epidemiology & …, 2024 - cambridge.org
To investigate the symptoms of SARS-CoV-2 infection, their dynamics and their discriminatory
power for the disease using longitudinally, prospectively collected information reported at …
power for the disease using longitudinally, prospectively collected information reported at …
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B. 1.1. 7 Variant
… Swift; Emma C Thomson; Jeremy Turner; Marianne Elizabeth Viljoen; Gary Albert; Iksung
Cho; Filip Dubovsky; Greg Glenn; Joy Rivers; Andreana Robertson; Kathy Smith …
Cho; Filip Dubovsky; Greg Glenn; Joy Rivers; Andreana Robertson; Kathy Smith …
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B. 1.1. 7 Variant (preprint)
BackgroundCovid-19 vaccines are urgently needed, especially against emerging variants.
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-…
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-…
[HTML][HTML] Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
…, EC Thomson, J Turner, ME Viljoen… - … England Journal of …, 2021 - Mass Medical Soc
Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…
'n Poolse Familie in Suid-Afrika: Masureik/Masuret
J Masureik, F Naudé, M Viljoen, M de Villiers - Familia, 2015 - journals.co.za
Soms kom ’n mens in jou soektogte ’n familie teë van wie daar min bekend is, en van wie
geen inligting in publikasies verskyn nie. So ’n van is Masureik/Masuret. Faan Naudé van …
geen inligting in publikasies verskyn nie. So ’n van is Masureik/Masuret. Faan Naudé van …
The Airs of Early Modern Ornament Prints
MC Viljoen - Oxford Art Journal, 2014 - academic.oup.com
… Whether Briot invented the figures and background landscape is uncertain, though Marianne
Grivel and Maxime Préaud have conjectured that Abraham Bosse was responsible for the …
Grivel and Maxime Préaud have conjectured that Abraham Bosse was responsible for the …